Chola Q2 FY27: Consol PAT +41% YoY to ₹1,630 Cr on margin expansion, cools 2% QoQ
PAT +40.59% YoY · revenue +23.75% · margins expanding · beat vs street
₹9,270.92 Cr
+23.75% YoY
₹1,630.34 Cr
+40.59% YoY
17.35%
+2.1pp YoY
₹19.09
Cholamandalam Investment and Finance reported consolidated PAT of ₹1,630.34 Cr for Q2 FY27, up 40.6% year-on-year from ₹1,159.61 Cr, on consolidated revenue of ₹9,270.92 Cr (+23.75% YoY). Profit growth outpaced revenue growth, pushing net profit margin to 17.36% from 15.23% a year ago (standalone NPM 17.63% vs 15.47%, per the regulatory ratio disclosure). Sequentially the picture is softer: revenue rose 4.68% QoQ but PAT slipped 1.56% QoQ from Q1 FY27's ₹1,656.22 Cr, and NPM compressed from Q1's 18.49% — a normal give-back after an unusually strong opening quarter rather than a trend reversal, and YoY remains the primary read per house convention. Standalone and consolidated results are effectively identical (PAT differs by just ₹0.27 Cr), so there is no basis divergence to flag.
Q2 FY-2027 vs prior quarters
The margin expansion sits on contained credit costs and improving asset quality rather than a one-off: impairment of financial instruments was ₹874.21 Cr, down from ₹922.06 Cr in Q1, while Gross Stage-3 (NPA) improved to 3.25% from 3.35% YoY and Net Stage-3 to 1.80% from 1.93% YoY, with provision coverage up to 45.32% from 43.23%. By segment, Vehicle Finance (PBT ₹979.17 Cr) and Loan Against Property (₹556.17 Cr) together drove the bulk of the ₹2,188.38 Cr segment PBT, with Home Loans contributing ₹269.02 Cr — consistent with the diversification thesis analysts have been tracking. The standalone loan book grew to ₹2,40,133.20 Cr from ₹2,17,571.16 Cr at FY26-end, a ~10.4% six-month rise that annualises close to the 23% FY27 AUM-growth guidance management gave on the Q1 concall; credit costs also look contained relative to the ~1.5% guided band, though the filing does not disclose a precise pre-tax ROA to check against the 3.5% minimum (Q1: 3.7%), so guidance delivery is assessed as broadly on-track rather than confirmed beat. No separate management press release was available in this filing to cross-check against the numbers.
The stock went into the print at ₹1,518, down 8.7% over the past month of trading.
For context: revenue is at a 6-quarter high.
FY27 AUM growth 23% likely (already achieved Q1), disbursements 22-23% growth, pre-tax ROA maintain 3.5% minimum (beat at 3.7% in Q1), credit costs hold ~1.5%. Cost of funds neutral for full year assuming 25-50 bps RBI rate hike.
— This quarter: met
Against our pre-result preview, which flagged Street expectations of ~₹8,900–9,100 Cr revenue and ~₹18.85 EPS for the quarter, the actual consolidated revenue of ₹9,270.92 Cr and basic EPS of ₹19.09 both came in above the expected range — a beat on both counts. Capital adequacy improved to 20.62% from 20.00% YoY even before the board's same-day approval of a QIP to raise up to ₹5,000 Cr, and the quarter also saw conversion of the remaining CCDs into 30.55 lakh equity shares and allotment of ₹2,000 Cr of perpetual NCDs — both consistent with the company funding its stated growth plan. The prior concall's cautious tone centered on cost-of-funds neutrality assuming a 25–50 bps RBI rate hike and holding credit costs near 1.5%; this quarter's contained impairment charge and improved NPA ratios are broadly consistent with that script.
W1
QIP pricing/dilution terms for the up-to-₹5,000 Cr raise approved this quarter — impact on EPS and ROE to confirm next
W2
Sequential NPM (18.49% Q1 → 17.36% Q2 consolidated) — confirm Q1 was the seasonal outlier, not a reversing trend
W3
Credit cost trajectory against management's ~1.5% guided band, given this quarter's impairment charge of ₹874.21 Cr and loan book growth pace vs the 23% FY27 AUM target
Clean typed statement, columns unambiguous (30.09.2026 Audited vs 30.06.2026 Un-audited vs 30.09.2025 Audited); standalone and consolidated nearly identical (two small subsidiaries + one JV, Group PAT only ₹0.27 Cr above standalone) — no material basis divergence; no exceptional items in either P&L this quarter or year-ago; board also approved a ₹5,000 Cr QIP same day.
Chola FY27: Growth Momentum Under Valuation Pressure
Street expects 24%+ revenue growth and solid PAT delivery, but stock trades near consensus targets—equity diversification and credit cost control the make-or-break reads.
Cholamandalam enters Q2 FY27 with a clear growth narrative: core vehicle finance remains the engine, but mortgage, consumer loans, MSME, and gold finance are scaling fast. The Street expects ~24–25% YoY revenue growth and 15–20% PAT growth for the full year—rates that signal both top-line momentum and controlled credit costs. The company has raised ₹55,000 crore in NCDs and converted ₹20,000+ crore of CCDs into fresh equity, building the capital base to fund this expansion. The test: can profitability growth keep pace with the lending mix shift, or will lower-yielding mortgages and gold loans compress margins?
What to Expect
~₹8,900–9,100 Cr
On-plan 24%+ YoY growth; Q1 FY27 was ₹8,957 Cr. Seasonal and mix-related variance normal.
~₹18.85
Analyst consensus (3 forecasters). FY27 full-year EPS guided at ₹81.1, implying steady Q-on-Q pace.
Watch for stability
Key risk if mortgage mix accelerates faster than vehicle finance. Equity diversification critical to offset NIM pressure.
NPA trends
Street assumes benign credit cost. Any NPA spike or credit cost guidance cut would weigh on PAT growth outlook.
A strong print would show revenue and PAT growth in the 24%+ and 15%+ range respectively, stable or improving NIMs despite loan-mix shifts, and management reaffirming full-year guidance without credit-cost surprises. A weak print would signal NIM compression beyond Street expectations, rising NPA, or slowing progress in non-vehicle segments despite the capital raise.
On Track?
Q1 FY27 (announced Jul 28) set the baseline: ₹8,957 Cr revenue and ₹1,656 Cr profit. Q2 needs to sustain that run-rate or show modest improvement to hit the Street's 24% YoY expectation. Analysts project FY27 revenue at ₹21,048 crore (+22.7% YoY) and full-year EPS of ₹81.1—a quarterly cadence averaging ~₹20.3 per share. Q2 at ₹18.85 is slightly below the quarterly average, which is typical mid-year (H1 often lighter than H2 in NBFC cycles). The capital raise and diversification into mortgages and gold loans are on plan; the earnings delivery hinges on credit cost stability.
What the Street Says
Since Last Quarter
1 · Capital Raise Completed
Board approved ₹55,000 Cr NCD programme (Jul 28). First tranche allotted: ₹2,000 Cr unsecured perpetual NCDs (Sep 1), ₹350 Cr secured NCDs (Aug 26). Programme provides dry powder for growth, but equity dilution from CCD conversions (43,000 CCDs → 30.55L shares, Sep 30) is ongoing. No dividend surprise flagged.
2 · Promoter Reclassification
Aug 26: Algavista Greentech (promoter entity) received NOC for reclassification. Promoter holding stable at ~49.2% (Q1 FY27). FII share inched down 42 bps QoQ to 24.45%; DII +71 bps to 20.62%. Routine corporate governance move.
3 · Trading Window & Result Intimation
Oct 1–30: Trading window closed for designated persons in connection with Q2 results. Board meeting set Oct 28 to approve audited standalone/consolidated P&L. Disclosure expected immediately after approval—watch for any delay or surprise statement.
4 · No Negative Surprises or Insider Activity
No pledges filed, no insider selling, no regulatory action. Sep 13: company clarified that elevated trading volume had no undisclosed information—consistent with market's seasonal churn.
The Setup
Cholamandalam enters Q2 results day as a growth story with a full quiver: vehicle finance scale, mortgage expansion, capital cushion, and Street conviction (32 analysts, 72% Buy). But the stock has given back summer gains—now 21% below ATH and trading near consensus price targets with limited near-term upside surprise built in. Results will be read against two yardsticks: (1) Did revenue and PAT growth hold the 24% and 15%+ pace? and (2) Are margins and credit costs stable enough to justify the dividend and guidance reaffirm? On the filing front, capital raise is done and dilution is visible; promoter commitment remains steady; no governance red flags. The valuation case rests on mortgage originations maturing and credit cycles staying benign.
Three Things to Watch on Oct 28
1. Margin Trajectory: Have Q2 NIMs held or compressed vs. Q1? Mortgage ramp-up is unavoidable, but if it erodes NIMs below 3.3%–3.4%, that signals pricing pressure and could spook the Street. Watch the yield on advances and cost of funds separately. 2. Credit Cost & NPA Ratio: Street assumes benign credit (1.0%–1.2% cost of credit as % of advances). Any spike, or NPA ratio creeping above 1.5%, would challenge the 15%+ PAT growth guidance. Vehicle portfolio typically clean; gold and MSME are the watch zones. 3. Diversification & Mortgage Mix: How much of Q2 originations came from non-vehicle segments? If mortgage + consumer + gold reached 30%+ of new originations, that validates the diversification thesis and supports the Street's optimism. If vehicle still >70%, growth will eventually stall.
Cholamandalam's Q2 is a straightforward test of execution under a growth thesis the Street already prices in. The company has the capital, the market tailwinds, and the management track record. The risk is not a miss—it's that the bar is high, and valuation leaves no room for a moderation. Results on Oct 28 will either reaffirm the diversification playbook or force a pullback if margins compress or credit costs spike. Coverage is deep and bullish, but the stock's sharp October decline suggests conviction is waning; a beat might reignite, a miss could accelerate the selloff.